Rheumatoid arthritis

American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision

Ann Rheum DisPublished Validation study

Authors' conclusion

Using the Boolean 2.0 criteria classifies, more patients as achieving remission and increases the agreement with index-based remission criteria without jeopardising predictive value for radiographic or functional outcomes.

Study context

Population
Participants with early or established rheumatoid arthritis (RA) in four randomised trials comparing bDMARDs with MTX or placebo1,101 early RA, 947 established RA
Participants
2,048 participants
Comparison
Boolean remission criteria with patient global assessment (PtGA) threshold 2 cm (Boolean2.0) vs original 1 cm threshold (Boolean1.0); agreement with Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) remission criteria
Outcome
Proportion in remission, agreement between Boolean and index-based remission criteria, and prediction of good physical function (HAQ ≤0.5) and radiographic non-progression
Follow-up
6 months
Methodological detailssecondary analysis of four randomised trials, external validation, pooled data from four randomised trials
  • Secondary analysis of four randomised trials
  • External validation
  • Pooled data from four randomised trials

Performance

As reported in the abstract

Proportion in remission · 6 months after treatment initiation

Proportion in remission · 6 months after treatment initiation

Established RA

Further findings

Prediction of radiographic non-progression and Health Assessment Questionnaire (HAQ) ≤0.5

Boolean2.0, SDAI and CDAI remission had similar positive likelihood ratios (LRs)
3.8-4.3
Omission of PtGA (BooleanX) worsened prediction of good functional outcomes

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Ann Rheum Dis. Published 24 October 2022. doi:10.1136/ard-2022-223413

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.